Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935251 | 0.91 | ALDH1A1 (0.54) | ALDH1A1LMNAPRMT1CA2CA1 | |
| SCHEMBL27890820 | 0.85 | CA1 (0.50) | ALDH1A1LMNACA2CA1ENPP2 | |
| SCHEMBL16879900 | 0.84 | ALDH1A1 (0.67) | ALDH1A1LMNAPRMT1CA2CA1 | |
| SCHEMBL8072061 | 0.83 | ALDH1A1 (0.57) | ALDH1A1LMNACA2CA1ENPP2 | |
| SCHEMBL5723996 | 0.83 | CA2 (0.73) | ALDH1A1LMNAPRMT1CA2CA1 | |
| SCHEMBL1429021 | 0.83 | CA1 (0.68) | ALDH1A1LMNACA2CA1NPSR1 | |
| SCHEMBL7974798 | 0.81 | CA1 (0.47) | ALDH1A1LMNACA2CA1ENPP2 | |
| SCHEMBL1395792 | 0.81 | CA2 (0.55) | ALDH1A1LMNACA2ENPP2EPHX1 | |
| SCHEMBL29976027 | 0.80 | GRM2 (0.50) | ALDH1A1LMNAPRMT1CAPN1GRIN2B | |
| Hydrochloric Acid SCHEMBL27589281 | 0.79 | CA2 (0.53) | ALDH1A1LMNACA2ENPP2GSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1341774-B1 | FUSED HETEROAROMATIC GLUCOKINASE ACTIVATORS | HOFFMANN LA ROCHE (CH) | 2006-02-01 | — | — | EP | claimed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | claimed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | claimed |
| CN-112851557-B | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2022-06-10 | — | — | CN | disclosed |
| CN-112851557-A | Sulfo-substituted biaryl compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| CN-1226294-C | Fused heteroaromatic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | CN | disclosed |
| EP-1572670-A1 | 5-SUBSTITUTED-PYRAZINE OR -PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052869-A1 | 5-SUBSTITUTED-PYRAZINE OR PYRIDINE GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| CN-1476438-A | Fused heteroaromatic glucokinase activators | - | 2004-02-18 | — | — | CN | disclosed |
| WO-2001007409-A1 | CARBAZOLE DERIVATIVES AND THEIR USE AS NEUROPEPTIDE Y5 RECEPTOR LIGANDS | ASTRAZENECA UK LIMITED (GB) | 2001-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793515-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | ALDH1A1 1386/4885LMNA 680/4885PRMT1 4394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.